Serum Amyloid A Is Associated With Obesity And Estrogen Receptor-negative Tumors In Postmenopausal Women With Breast Cancer.

dc.creatorSantana, Aline Barros
dc.creatorGurgel, Maria Salete Costa
dc.creatorde Oliveira Montanari, Joelma Ferreira
dc.creatorBonini, Flavia Muraro
dc.creatorde Barros-Mazon, Silvia
dc.date2013-Feb
dc.date2015-11-27T13:31:13Z
dc.date2015-11-27T13:31:13Z
dc.date.accessioned2018-03-29T01:17:01Z
dc.date.available2018-03-29T01:17:01Z
dc.identifierCancer Epidemiology, Biomarkers & Prevention : A Publication Of The American Association For Cancer Research, Cosponsored By The American Society Of Preventive Oncology. v. 22, n. 2, p. 270-4, 2013-Feb.
dc.identifier1538-7755
dc.identifier10.1158/1055-9965.EPI-12-1020
dc.identifierhttp://www.ncbi.nlm.nih.gov/pubmed/23300020
dc.identifierhttp://repositorio.unicamp.br/jspui/handle/REPOSIP/200433
dc.identifier23300020
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/1300666
dc.descriptionSerum amyloid A (SAA) is an acute-phase protein and also an adipokine, which has been associated with the development and prognosis of breast cancer. In the present study, we investigated the association between obesity and SAA in postmenopausal women with breast cancer and its relationship with clinicopathologic characteristics of tumors. Patients were grouped as nonobese or overweight/obese based on body mass index (BMI) plus waist circumference measurement. Serum SAA concentrations were determined by high-sensitivity micro-latex agglutination tests, detected by nephelometry. Serum SAA concentrations were higher in overweight/obese (P = 0.008) patients and this condition was dependent on obesity (BMI and waist circumference), as further shown by multivariate linear regression analysis done for SAA (P = 0.01). Concentrations of SAA were also higher in patients with estrogen receptor-negative (ER(-)) tumors than in those with estrogen receptor-positive (ER(+); P = 0.033). Our results suggest a possible role for SAA in the development and prognosis of obesity-related breast cancer. A follow-up study of this population to assess overall and disease-free survival is in course and should bring contribution to evaluate the clinical role of SAA in breast cancer in the context of obesity.
dc.description22
dc.description270-4
dc.languageeng
dc.relationCancer Epidemiology, Biomarkers & Prevention : A Publication Of The American Association For Cancer Research, Cosponsored By The American Society Of Preventive Oncology
dc.relationCancer Epidemiol. Biomarkers Prev.
dc.rightsfechado
dc.rights
dc.sourcePubMed
dc.subjectAged
dc.subjectAged, 80 And Over
dc.subjectBody Mass Index
dc.subjectBreast Neoplasms
dc.subjectFemale
dc.subjectHumans
dc.subjectMiddle Aged
dc.subjectObesity
dc.subjectPostmenopause
dc.subjectPrognosis
dc.subjectReceptors, Estrogen
dc.subjectRisk Factors
dc.subjectSerum Amyloid A Protein
dc.subjectTumor Markers, Biological
dc.titleSerum Amyloid A Is Associated With Obesity And Estrogen Receptor-negative Tumors In Postmenopausal Women With Breast Cancer.
dc.typeArtículos de revistas


Este ítem pertenece a la siguiente institución